Return to listings page

May 11, 2011

Long-Acting Opioid Class REMS: An Update of New Requirements and Implications for Us All

Last month FDA issued requirements for the long awaited Long-Acting Opioid Class REMS programs. This webinar will focus on the components of the program and the implications and precedents for industry.


  • Review the Long-Acting Opioids Class REMS components
  • Explore the implications for manufacturers
  • Discuss the precedents established for industry

Jeff Fetterman, President - ParagonRx

Webinar Slide Set:










Session Replay:

To speak to a ParagonRx team member about our monthly webinars
call 888.459.8080 or email